1. In Vivo Evolution of CTX-M-215, a Novel Narrow-Spectrum β-Lactamase in an Escherichia coli Clinical Isolate Conferring Resistance to Mecillinam
- Author
-
Yohei Doi, Guoping Hu, Dan Li, Mengyun Yin, Qinglan Guo, Yu Zhang, Xuefei Zhang, Minggui Wang, Zhen Shen, and Chengli Fang
- Subjects
Pharmacology ,0303 health sciences ,Cefotaxime ,030306 microbiology ,medicine.drug_class ,Chemistry ,030302 biochemistry & molecular biology ,Cephalosporin ,biochemical phenomena, metabolism, and nutrition ,bacterial infections and mycoses ,medicine.disease_cause ,Narrow spectrum ,Microbiology ,03 medical and health sciences ,Infectious Diseases ,Plasmid ,Mechanisms of Resistance ,In vivo ,polycyclic compounds ,medicine ,Pharmacology (medical) ,Mecillinam ,Escherichia coli ,medicine.drug - Abstract
Here, we report a novel narrow-spectrum β-lactamase CTX-M-215 identified in an Escherichia coli clinical isolate in China and conferring high-level resistance to mecillinam but not to cefotaxime. CTX-M-215 differed from CTX-M-125, a CTX-M extended-spectrum β-lactamase (ESBL), by an N132D substitution, which decreased hydrolytic activities toward penicillins and cephalosporins except for mecillinam. High similarity was observed between CTX-M-215- and CTX-M-125-bearing plasmids, carried by different isolates in the same patient, indicating in vivo evolution of CTX-M-215 from CTX-M-125.
- Published
- 2020